Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Chief Legal Officer | June 10, 2026 | June 12, 2026 |
| Zyla Life SciencesEGLT · Entity 148990 | SVP, GC & Chief Compliance Off | July 03, 2017 | July 06, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,576 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Tax withholding · Disposed 1,081 · Balance 32,576 F1: Includes 5,723 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 5,723 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.
Zyla Life Sciences
Report date July 03, 2017 · Filed July 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,514 |
Reported balance
After 2017-07-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-07-03 · Sale · Disposed 806 · Balance 29,514 F1: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes 1,500 shares acquired under the Egalet Corporation Employee Stock Purchase Plan on June 30, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes 1,500 shares acquired under the Egalet Corporation Employee Stock Purchase Plan on June 30, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:41 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 1,081 | $13.10 | $14,161.10 |
DisclosureSEC source: 0001677896-26-000008 · form4-06122026_080618.xml · nonDerivative · entry 1 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,576 F1 · balance_after: Includes 5,723 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantCommon Stock | 24,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001677896-26-000006 · form4-05262026_040505.xml · nonDerivative · entry 1 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,934 F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,563 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001677896-26-000004 · form4-05072026_080504.xml · derivative · entry 9 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,437 Underlying: Common Stock · 12,563 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F7 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $13.43 | $0.00 |
DisclosureSEC source: 0001677896-26-000004 · form4-05072026_080504.xml · derivative · entry 8 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 62,500 shares Expires 2034-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F6 · derivative.exercise_date: Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 400 | $23.71 | $9,484.00 |
DisclosureSEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 7 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,634 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 9,253 | $22.70 | $210,029.22 |
DisclosureSEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 6 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,034 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F5 · price: The reported securities were sold in multiple transactions at prices ranging from $22.15 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 22,839 | $21.22 | $484,540.80 |
DisclosureSEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 5 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,287 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F4 · price: The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 5,196 | $19.78 | $102,783.12 |
DisclosureSEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 4 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,126 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F3 · price: The reported securities were sold in multiple transactions at prices ranging from $19.50 to $19.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 37,375 | $18.91 | $706,836.00 |
DisclosureSEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 3 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,322 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $18.50 to $19.495. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 12,563 | $8.04 | $101,006.52 |
DisclosureSEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 2 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 62,500 | $13.43 | $839,375.00 |
DisclosureSEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 1 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:24 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0001677896-26-000002 · form4-03022026_090313.xml · derivative · entry 1 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:17 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 1,016 | $4.10 | $4,165.60 |
DisclosureSEC source: 0001470831-25-000410 · form4.xml · nonDerivative · entry 1 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,634 F1 · balance_after: Includes 3,634 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 22:51 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001578563-25-000029 · primary_doc.xml · derivative · entry 1 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:08 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $13.43 | $0.00 |
DisclosureSEC source: 0001578563-24-000320 · primary_doc.xml · derivative · entry 1 VARKI PAUL · CIK 0001677896 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 16:47 UTC | Zyla Life Sciences EGLT · Entity 148990 | SaleCommon Stock | 806 | $2.35 | $1,894.10 |
DisclosureSEC source: 0001179110-17-010176 · edgar.xml · nonDerivative · entry 1 VARKI PAUL · CIK 0001677896 · SVP, GC & Chief Compliance Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,514 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 1,500 shares acquired under the Egalet Corporation Employee Stock Purchase Plan on June 30, 2017. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:41 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001179110-17-008928 · edgar.xml · derivative · entry 1 VARKI PAUL · CIK 0001677896 · SVP, GC & Chief Compliance Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: 25% of the options will vest on the later of (i) the 6-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $3.33 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. 25% of the options will vest on the later of (i) the 12-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.05 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. The remaining 50% of the options will vest on the later of (i) the 24-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.76 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 17:05 UTC | Zyla Life Sciences EGLT · Entity 148990 | SaleCommon Stock | 806 | $5.05 | $4,070.30 |
DisclosureSEC source: 0001179110-17-005584 · edgar.xml · nonDerivative · entry 1 VARKI PAUL · CIK 0001677896 · SVP, GC & Chief Compliance Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,820 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 16:58 UTC | Zyla Life Sciences EGLT · Entity 148990 | SaleCommon Stock | 806 | $7.75 | $6,246.50 |
DisclosureSEC source: 0001179110-17-000254 · edgar.xml · nonDerivative · entry 1 VARKI PAUL · CIK 0001677896 · SVP, GC & Chief Compliance Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,626 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 16:30 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001179110-16-032595 · edgar.xml · derivative · entry 1 VARKI PAUL · CIK 0001677896 · SVP, GC & Chief Compliance Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-12-06 F1 · derivative.exercise_date: The option vests with respect to one-fourth of the underlying shares on the first anniversary of the grant date and with respect to one-forty eighth of the underlying shares each month thereafter until fully vested. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 16:25 UTC | Zyla Life Sciences EGLT · Entity 148990 | SaleCommon Stock | 806 | $7.56 | $6,093.36 |
DisclosureSEC source: 0001179110-16-030281 · edgar.xml · nonDerivative · entry 1 VARKI PAUL · CIK 0001677896 · SVP, GC & Chief Compliance Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,432 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on November 16, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.